Phase IB/II Study of Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Mocetinostat (Primary) ; Brentuximab vedotin
- Indications Hodgkin's disease
- Focus Adverse reactions
- 25 Apr 2017 Planned number of patients changed from 44 to 7.
- 25 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 05 May 2015 New trial record